Top 10 bladder cancer articles and videos of 2024

There has been a lot of news about bladder cancer over the past year. To celebrate these breakthroughs, the editorial staff at Urology Times® are showcasing our top content on bladder cancer from 2024.

Management of BCG-unresponsive NMIBC

“We discuss available bladder-sparing treatment options for BCG-unresponsive [non–muscle invasive bladder cancer] as well as avenues of exploration for future treatments,” write Rachel Passarelli, MD, and Vignesh T. Packiam, MD. Read their article here

Dr. Soon-Shiong discusses the FDA approval of N-803 in NMIBC

In April 2024, the FDA approved N-803 (Anktiva, nogapendekin alfa inbakicept-pmln), a first-in-class IL-15 receptor agonist immunotherapy for use in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors. In this interview, Patrick Soon-Shiong, MD, discusses the significance of the FDA approval for immunotherapy in NMIBC. Watch the video here

TAR-200 may bolster NMIBC treatment options

In this interview, Mark D. Tyson, MD, MPH, discusses TAR-200 and other novel investigational treatments for NMIBC. Read the interview here

Apalutamide holds potential in NMIBC, expert says

In this interview, Edward M. Messing, MD, discusses the study, “A Randomized Trial of Apalutamide in Non-Muscle Invasive Bladder Cancer (NCI INT 22-09-01)*,” which was highlighted at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Read the interview here

Blue light cystoscopy decreases risk of recurrence, progression in NMIBC

Data from the BRAVO study presented at the 2024 American Urological Association Annual Meeting showed that blue light cystoscopy was associated with improved clinical outcomes compared with white light cystoscopy in patients with NMIBC within the Veterans Affairs Healthcare System.Learn more here

BCG-unresponsive NMIBC: Advancements are finally moving the needle

This article from Urology Times Co–Editor in Chief Michael S. Cookson, MD, MMHC, FACS, highlights the notable advancements seen in NMIBC. Read the article here

EV-302 data on EV/pembro in urothelial carcinoma published in NEJM

Data from the phase 3 EV-302 trial (NCT04223856) have been published in the New England Journal of Medicine, showing that the combination of enfortumab vedotin-ejfv (Padcev, EV) and pembrolizumab (Keytruda) extended overall survival and progression-free survival vs platinum-based chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma. Learn more here

FDA accepts IND application for RAG-01 in NMIBC

The FDA has cleared an investigational new drug application for the small activating RNA therapy RAG-01 for the management of BCG-unresponsive NMIBC, announced Ractigen Therapeutics, the developer of the therapy, in a news release. Read more here

Photodynamic therapy TLD-1433 shows initial promise in NMIBC

The primary and secondary objectives have been met in a phase 2 study (NCT03945162) of the photodynamic therapy TLD-1433, being explored as a treatment option for patients with BCG-unresponsive NMIBC carcinoma in situ, according to a news release from Theralase Technologies, the developer of the compound. Learn more here

Lymph nodes in bladder cancer: Past, present, and future

"Based on the LEA and S1011 trials, it has become clear that patients do not benefit from an extended LND, and a standard bilateral pelvic LND is the standard of care," write Amir Soltani-Tehrani, MD, and Kamal S. Pohar, MD. Read their article here